Archives

  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-05
  • 2022-04
  • 2021-03
  • 2020-08
  • 2020-07
  • 2018-07
  • br consultant advisory member for Astellas Pharma AstraZeneca Bayer Genmab

    2022-09-13


    consultant/advisory member for Astellas Pharma, AstraZeneca, Bayer, Genmab, Genentech, GlaxoSmithKline, Janssen, Medivation, Orion Pharma, Pfizer and Sanofi. J.S. de Bono is a National Institute for Bortezomib Health Research (NIHR) Senior Investigator. The views expressed in this article are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health.
    Funding/Support and role of the sponsor: Work in the Plymate laboratory was supported by a Department of Defense Prostate Cancer Research Program (W81XWH-14-2-0183, W81XWH-12-PCRP-TIA, and W81XWH-13-2-0070), the Pacific Northwest Prostate Cancer SPORE (P50CA97186), the Institute for Prostate Cancer Research (IPCR), Veterans Affairs Research Program, NIH/National Cancer Institute (P01CA163227), and the Prostate Cancer Foundation. Work in the Luo laboratory was supported by the Patrick C. Walsh Prostate Cancer Research Fund, NIH grant R01 CA185297, and US Department of Defense Prostate Cancer Research Program grant W81XWH-15-2-0050. Work in the de Bono laboratory was supported by funding from the Movember Foundation/ Prostate Cancer UK (CEO13-2-002), the US Department of Defense (W81XWH-13-2-0093), the Prostate Cancer Foundation (20131017 and 20131017-1), Stand Up To Cancer (SU2C-AACR-DT0712), Cancer Research UK (CRM108X-A25144), and the UK Department of Health through an Experimental Cancer Medicine Centre grant (ECMC-CRM064X). A. Sharp is supported by the Medical Research Council (MR/M018618/1), the Academy of Medical Sciences/Prostate Cancer UK (SGCL15), and a Prostate Cancer Foundation Young Investigator Award.
    Acknowledgements: We thank the patients and their Bortezomib for their participation in these studies.
    Appendix A. Supplementary data
    References
    [3] Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N EnglJ Med 2013;368:138–48. [4] Ryan CJ, Smith MR, Fizazi K, et al. Abiraterone acetate plus predni-sone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, place-bo-controlled phase 3 study. Lancet Oncol 2015;16:152–60. [5] James ND, de Bono JS, Spears MR, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med 2017;377:338–51.
    Please cite this article in press as: Sharp A, et al. Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer. Eur Urol (2019), https://doi.org/10.1016/j.eururo.2019.04.006
    [9] Fizazi K, Scher HI, Miller K, et al. Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial. Lancet Oncol 2014;15:1147–56.
    [11] De Laere B, van Dam PJ, Whitington T, et al. Comprehensive profiling of the androgen receptor in liquid biopsies from castration-resistant prostate cancer reveals novel intra-AR structural variation and splice variant expression patterns. Eur Urol 2017;72:192–200. [12] Qu F, Xie W, Nakabayashi M, et al. Association of AR-V7 and prostate-specific antigen RNA levels in blood with efficacy of abir-aterone acetate and enzalutamide treatment in men with prostate cancer. Clin Cancer Res 2017;23:726–34. [13] Scher HI, Graf RP, Schreiber NA, et al. Nuclear-specific AR-V7 protein localization is necessary to guide treatment selection in metastatic castration-resistant prostate cancer. Eur Urol 2017;71:874–82. [14] Scher HI, Lu D, Schreiber NA, et al. Association of AR-V7 on circu-lating tumor cells as a treatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer. JAMA Oncol 2016;2:1441–9.